Download Files:
Terfenadine
$66 – $73
Products Details
Product Description
– Terfenadine ((±)-Terfenadine) is a potent open-channel blocker of hERG with an IC50 of 204 nM[1]. Terfenadine, an H1 histamine receptor antagonist, acts as a potent apoptosis inducer in melanoma cells through modulation of Ca2+ homeostasis. Terfenadine induces ROS-dependent apoptosis, simultaneously activates Caspase-4, -2, -9[2].
Web ID
– HY-B1193
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C32H41NO2
References
– [1]Kamiya K, et al. Molecular determinants of hERG channel block by terfenadine and cisapride. J Pharmacol Sci. 2008 Nov;108(3):301-307.|[2]Nicolau-Galmés F, et al. Terfenadine induces apoptosis and autophagy in melanoma cells through ROS-dependent and -independent mechanisms. Apoptosis. 2011 Dec;16(12):1253-67.|[3]An L, et al. Terfenadine combined with epirubicin impedes the chemo-resistant human non-small cell lung cancer both in vitro and in vivo through EMT and Notch reversal. Pharmacol Res. 2017 Oct;124:105-115.
CAS Number
– 50679-08-8
Molecular Weight
– 471.67
Compound Purity
– 99.93
SMILES
– OC(C1=CC=C(C(C)(C)C)C=C1)CCCN2CCC(C(C3=CC=CC=C3)(O)C4=CC=CC=C4)CC2
Clinical Information
– Launched
Research Area
– Cancer; Inflammation/Immunology; Endocrinology
Solubility
– DMSO : ≥ 50 mg/mL|H2O : 0.67 mg/mL (ultrasonic)
Target
– Apoptosis;Caspase;Histamine Receptor;Na+/Ca2+ Exchanger;Potassium Channel
Isoform
– Caspase 2;Caspase 4;Caspase 9;H1 Receptor
Pathway
– Apoptosis;GPCR/G Protein;Immunology/Inflammation;Membrane Transporter/Ion Channel;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
